Your browser doesn't support javascript.
An overview of vaccine development for COVID-19.
Shahcheraghi, Seyed H; Ayatollahi, Jamshid; Aljabali, Alaa Aa; Shastri, Madhur D; Shukla, Shakti D; Chellappan, Dinesh K; Jha, Niraj K; Anand, Krishnan; Katari, Naresh K; Mehta, Meenu; Satija, Saurabh; Dureja, Harish; Mishra, Vijay; Almutary, Abdulmajeed G; Alnuqaydan, Abdullah M; Charbe, Nitin; Prasher, Parteek; Gupta, Gaurav; Dua, Kamal; Lotfi, Marzieh; Bakshi, Hamid A; Tambuwala, Murtaza M.
  • Shahcheraghi SH; Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Ayatollahi J; Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Aljabali AA; Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Shastri MD; Department of Pharmaceutics & Pharmaceutical Technology, Yarmouk University, Irbid, Jordan.
  • Shukla SD; School of Pharmacy & Pharmacology, University of Tasmania, Hobart, Australia.
  • Chellappan DK; Priority Research Centre for Healthy Lungs, School of Medicine & Public Health, The University of Newcastle, Callaghan, Australia.
  • Jha NK; Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
  • Anand K; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Katari NK; Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences & National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa.
  • Mehta M; Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad 502329, India.
  • Satija S; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia.
  • Dureja H; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
  • Mishra V; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia.
  • Almutary AG; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
  • Alnuqaydan AM; Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India.
  • Charbe N; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
  • Prasher P; Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Saudi Arabia.
  • Gupta G; Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Saudi Arabia.
  • Dua K; Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Libertador Bernardo O'Higgins, Santiago 340, Región Metropolitana, Chile.
  • Lotfi M; Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, India.
  • Bakshi HA; School of Pharmaceutical Sciences, Suresh Gyan Vihar University, Jaipur, India.
  • Tambuwala MM; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Ther Deliv ; 12(3): 235-244, 2021 03.
Article in English | MEDLINE | ID: covidwho-1100274
ABSTRACT
The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Ther Deliv Year: 2021 Document Type: Article Affiliation country: Tde-2020-0129

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Ther Deliv Year: 2021 Document Type: Article Affiliation country: Tde-2020-0129